Takeda has secured the Japanese MHLW approval for its FRUZAQLA to treat unresectable advanced or recurrent colorectal cancer ...

The EMA CHMP has recommended granting approval for AstraZeneca’s Fasenra for eosinophilic granulomatosis with polyangiitis ...

The EC has granted marketing authorisation to LEO Pharma’s Anzupgo cream for treating adults with moderate to severe chronic ...

UCB has received US FDA approval for BIMZELX (bimekizumab-bkzx) to treat adults with three inflammatory conditions.

The US FDA has granted approval for AstraZeneca's FluMist, a needle-free nasal spray influenza vaccine for ...

Vicebio has raised $100m in a Series B funding round led by TCGX. Credit: MargJohnsonVA via Shutterstock. UK-based startup ...

The European Commission (EC) has conditionally approved Ipsen ’s Iqirvo (elafibranor) for the treatment of primary biliary ...

New safety data shows an absence of post-injection syndrome, a rare and serious side effect of long-acting olanzapine.

Pancreatic cancer is resistant to conventional therapies, but cutting-edge research may improve survival rates and patient ...

Under the terms of the agreement, Sanofi will gain an exclusive right to first negotiation for the CNS-penetrant, VTX3232.

Zevra Therapeutics has gained FDA approval for Miplyffa (arimoclomol) to treat Niemann-Pick disease type C (NPC).

Takeda UK has announced the UK's MHRA approval of fruquintinib for adults with metastatic colorectal cancer (CRC).